Amorphical Ltd.

Amorphical Ltd. is an innovative company focused on developing natural-based medicines and dietary supplements that utilize amorphous calcium carbonate (ACC) to enhance calcium absorption and support overall health. Founded in 2004 and headquartered in Israel, Amorphical Ltd. specializes in the development of natural-based medicines.

The company has conducted one significant funding round, raising USD 30. 00 mn in Series F funding in December 2020 from unspecified investors. The CEO and founder, Yossi Ben, has played an integral role in the company's strategic direction. Amorphical's current valuation stands at USD 160.

00 mn, showcasing its potential in the healthcare sector. Amorphical specializes in the development and manufacture of innovative natural-based medicines and dietary supplements that utilize amorphous calcium carbonate (ACC) as a core ingredient. Their flagship product, ACC, is a nanomaterial with a unique amorphous molecular structure that is designed to improve calcium absorption and manage the body's acidic pH levels. The primary end uses for these products include addressing calcium deficiencies, treating inflammatory diseases, and supporting bone health.

Amorphical targets healthcare providers and patients with conditions such as osteoporosis and chronic inflammatory disorders, marketing its products across multiple international regions. Amorphical generates revenue through the direct sale of its proprietary ACC-based products to healthcare professionals, retailers, and potentially direct-to-consumer channels. The revenue model is structured around partnerships with healthcare institutions and sales to wholesalers, focusing on bulk orders and individual sales to pharmacies. While specific pricing details are not disclosed, the company's emphasis remains on delivering high-quality solutions that cater to the needs of patients and healthcare providers.

In December 2020, Amorphical Ltd. raised USD 30. 00 mn in Series F funding to support clinical trials of its drug for second-degree prostate cancer. The company plans to utilize this funding to advance its research and development initiatives, focusing on launching new products that target specific health issues.

Additionally, Amorphical aims to expand into new markets, particularly regions with increasing demand for advanced nutritional supplements, thereby enhancing its global presence.